Presence or absence of anti-FVIII immunoglobulin isotypes and IgG subclasses as predictors of remission and survival in 81 patients with AHA
| Variable . | Partial remission . | Complete remission . | Overall survival . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | aHR (95% CI) . | HR (95% CI) . | aHR (95% CI) . | HR (95% CI) . | aHR (95% CI) . | |
| IgG1 positive (n = 71) | 0.54 (0.27-1.07) | — | 1.02 (0.44-2.40) | — | 0.76 (0.26-2.20) | — |
| IgG2 positive (n = 62) | 0.53 (0.31-0.92)* | 0.56 (0.31-1.03) | 0.85 (0.45-1.63) | — | 0.97 (0.39-2.40) | — |
| IgG3 positive (n = 33) | 1.09 (0.68-1.75) | — | 0.85 (0.49-1.49) | — | 0.85 (0.40-1.81) | — |
| IgG4 positive (n = 79) | 0.55 (0.13-2.27) | — | 0.30 (0.07-1.25) | — | 21 (0.001-∞) | — |
| IgA positive (n = 37) | 0.63 (0.39-1.02) | — | 0.34 (0.19-0.61)*** | 0.35 (0.18-0.68)** | 3.46 (1.54-7.75)** | 2.62 (1.11-6.22)* |
| IgM positive (n = 7) | 1.06 (0.48-2.31) | — | 0.86 (0.34-2.17) | — | 0.62 (0.15-2.63) | — |
| Variable . | Partial remission . | Complete remission . | Overall survival . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | aHR (95% CI) . | HR (95% CI) . | aHR (95% CI) . | HR (95% CI) . | aHR (95% CI) . | |
| IgG1 positive (n = 71) | 0.54 (0.27-1.07) | — | 1.02 (0.44-2.40) | — | 0.76 (0.26-2.20) | — |
| IgG2 positive (n = 62) | 0.53 (0.31-0.92)* | 0.56 (0.31-1.03) | 0.85 (0.45-1.63) | — | 0.97 (0.39-2.40) | — |
| IgG3 positive (n = 33) | 1.09 (0.68-1.75) | — | 0.85 (0.49-1.49) | — | 0.85 (0.40-1.81) | — |
| IgG4 positive (n = 79) | 0.55 (0.13-2.27) | — | 0.30 (0.07-1.25) | — | 21 (0.001-∞) | — |
| IgA positive (n = 37) | 0.63 (0.39-1.02) | — | 0.34 (0.19-0.61)*** | 0.35 (0.18-0.68)** | 3.46 (1.54-7.75)** | 2.62 (1.11-6.22)* |
| IgM positive (n = 7) | 1.06 (0.48-2.31) | — | 0.86 (0.34-2.17) | — | 0.62 (0.15-2.63) | — |
Hazard ratios (HRs) from Cox regression models with time to end point as dependent variable and presence/absence of immunoglobulin isotype or subclass as independent variable. aHRs were adjusted for age group (≤ or >74 y), gender (female or male), underlying disorder (malignancy, autoimmunity, pregnancy present or not), baseline FVIII:C (< or ≥1 IU/dL), NBA inhibitor titer (≤ or >20 BU/mL), and WHO-PS (≤ or >2) as categorical variables. Adjustment was not done for isotypes/subclasses that were not significant in univariate analysis. An HR/aHR < 1 denotes a slower rate in achieving the end point; an HR/aHR > 1 indicates a faster rate in achieving the end point.
HR, hazard ratio; —, not applicable because of insignificant result in univariate analysis.
P < .05, **P < .01, ***P < .001.